Though biologics are generally used in patients that fail to respond to previous therapies, the study reveals that early use of anti-TNF- α therapy in children diagnosed with moderate to severe Crohn’s disease is more effective at achieving remission than the current standard of treatment.
At one year, 85 percent of the patients receiving anti-TNF- α therapy achieved corticosteroid-free clinical remission.
More Articles on Gastroenterology:
10 Statistics on GI/Endoscopy Revenue Per Case Across the US
2014 CPT Code Update: GI/Endoscopy
FDA Regulation: 10 Elements of a New Drug Application for FMT
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
